Carotegrast methyl is a Small Molecule owned by EA Pharma, and is involved in 12 clinical trials, of which 10 were completed, 1 is ongoing, and 1 is planned.

Carotegrast methyl (AJM-300) is an alpha4 integrin antagonist. Apha4 integrins such as alpha4beta1 and alpha4beta7 which are expressed on the leukocyte cell surface mediate the inflammatory processes leading to tissue damage and disease. These glycoprotein receptors modulate cell adhesion via interaction with their primary ligands, vascular cell adhesion molecule (VCAM) and mucosal addressing cell adhesion molecule (MadCAM) which is expressed in the affected tissue.

The revenue for Carotegrast methyl is expected to reach a total of $1.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Carotegrast methyl NPV Report.

Carotegrast methyl was originated by Ajinomoto Co and is currently owned by EA Pharma. Eisai is the other company associated in development or marketing of Carotegrast methyl.

Carotegrast methyl Overview

Carotegrast Methyl (Carogra) was an alpha4 integrin antagonist. It was formulated as film-coated tablets for oral route of administration, Carogra was indicated for the treatment of ulcerative colitis. It was a small-molecule alpha-4 integrin antagonist that inhibits the binding of alpha 4-beta 1/alpha 4-beta7 integrin-expressing cells to VCAM-1/MAdCAM-1.

Eisai Overview

Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY756,226 million for the fiscal year ended March 2022 (FY2022), an increase of 17.1% over FY2021. In FY2022, the company’s operating margin was 7.1%, compared to an operating margin of 8% in FY2021. In FY2022, the company recorded a net margin of 6.3%, compared to a net margin of 6.5% in FY2021. The company reported revenues of JPY174,364 million for the second quarter ended September 2022, a decrease of 5.4% over the previous quarter.

Quick View – Carotegrast methyl

Report Segments
  • Innovator (NME)
Drug Name
  • Carotegrast methyl
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.